Background: The aims of the study are 1) to assess antiarrhythmic prophylaxis efficacy during the first 2 months after radiofrequency ablation (ARF) sustain SR were: males (82.9% vs. 62.2%; p = 0.018), younger patients (44.8 ± 12.7 vs. 52.5 ± 9.9; p = 0.0001), patients with smaller left atrium diameter (4.05 ± ± 0.49 cm vs. 4.25 ± 0.51 cm; p = 0.04), and those without any AF recurrence during the first 2 months after ARF (78.7% vs. 35.6%; p < 0.0001). In the multivariable analysis, the independent risk factors for LAFR were hypertension (p < 0.001) and persistent AF (p = 0.014). Conclusions: Antiarrhythmic prophylaxis does not affect the number of AF recurrences during the first 2 months after ablation. SR maintenance during a blanking period after AF ablation is a positive prognostic factor in long-term follow-up. Persistent AF and hypertension are independent risk factors for late AF recurrence after pulmonary vein isolation. (Cardiol J 2014; 21, 4: 384-391) 
Introduction
Atrial fibrillation (AF) is the most common supraventricular tachyarrhythmia and is responsible for one third of all hospital admissions due to arrhythmia. The incidence of AF is 1-2% of the total population and increases with the age [1, 2] up to 8% in the population over 80 years [3] .
Radiofrequency ablation with pulmonary vein isolation (PVI) is an accepted method for treatment of AF [4] . Despite the sophisticated technology involved in AF ablation therapy, however, AF recurrence may be observed either in the early period after PVI or during long-term follow-up. In some patients, temporal exacerbation of AF is observed during the early period after PVI. Furthermore, it is not clearly defined when the early periods ends and when the late period starts. Previously, AF recurrences during the first weeks after PVI were treated as a non-significant factor, but nowadays they are regarded to have an impact on long-term PVI failure [5] [6] [7] .
Antiarrhythmic prophylaxis with limited efficacy may result in adverse effects [8] [9] [10] . The role of early AF recurrence is unclear.
This study has three main aims: 1) to find the risk factors for early and late recurrence of AF after PVI, 2) to assess the importance of early AF recurrence, and 3) to check the usefulness of antiarrhythmic prophylaxis during the early period after PVI.
Methods
The study was conducted in prospective randomized mode. A total number of 210 consecutive patients who had undergone PVI due to AF were analyzed (2003) (2004) (2005) (2006) (2007) . In all patients, reversible causes of AF were excluded, as was pre-procedural left atrial appendage thrombus. The inclusion criteria were: 1) first PVI due to AF; 2) age above 18 years; and 3) sinus rhythm (SR) during the first 24 h after PVI. The exclusion criteria were: 1) reversible cause of AF; 2) bradycardia of 50 bpm or less, atrioventricular or intraventricular blocks; 3) contraindications to antiarrhythmic agents used during study (in case of contraindications to amiodarone, sotalol was used); and 4) PVI procedure with heart tamponade complication.
The study group was randomly divided into three groups: -Group 1: patients without any antiarrhythmic agent (G1); -Group 2: patients receiving amiodarone (or sotalol in case of amiodarone contraindications) (G2); and -Group 3: patients with last ineffective antiarrhythmic agent used before PVI (G3). The above therapy scheme was continued for 2 months after PVI.
At discharge, all patients were planned for at least two 24-h Holter electrocardiography (ECG) registration, followed by a control visit after the first and second months after PVI. They were also asked to provide symptoms registration during the first 2 months after PVI and to complete ECG documentation in case of any arrhythmia symptoms occurrence. After a minimum period of 2 years after PVI, the patients were called for a follow-up visit, or medical data were obtained through a telephone call. Every episode of AF lasting 30 s or more was classified as AF recurrence (Fig. 1) .
The AF recurrence rate was assessed after an analysis of all available rhythm recordings: 24-h Holter monitoring at 30 and 60 days after PVI and every ECG registration made on occurrence of symptoms suggesting arrhythmia.
Due to different protocols on result description among different centers, the medical data gathered during follow-up were inconsistent. To make them comparable, the results were divided into groups: -patients with successful PVI:
• patients without AF recurrence;
• patients with a single AF episode; -patients with unsuccessful PVI:
• patients with subjective improvement but insignificant reduction in number of AF episodes; • patients without change in AF intensity. During short-term observation, two groups of patients, those without AF recurrence and those with a single episode of AF, were treated as successful PVI procedures, whereas the groups with a reduction in severity of AF and without any change were regarded as procedural failures. Analysis was performed separately in the subgroups (no AF, single AF episode, unsuccessful PVI) and the cumulative successful/unsuccessful groups.
During long-term observation, there were only two groups considered: patients with SR and those with documented recurrence of AF. Clinically important, AF recurrence was defined as any documented, ECG-recorded episode of AF lasting at least 30 s.
The study was approved by the local bioethical committee and all patients gave their informed consent.
Antiarrhythmic treatment
Antiarrhythmic drugs (AAD) were withdrawn 7 days before the procedure in case of amiodarone, beta-blocker, propafenone, and sotalol use, with gradual dosage reduction stopped 2 days before PVI. Antiarrhythmic agents were initiated during the first 24 h after the procedure.
Pulmonary vein isolation
In all cases, segmental PVI was done with a 4 mm-tip not irrigated conventional radiofrequency catheter (Marinr, Medtronic) with 30-35 W power and a 50 o C cutoff (RF generator Atakr II, Medtronic). Pulmonary veins were mapped with a 10-pole circular diagnostic catheter with variable diameter (Lasso 2515, Biosense-Webster). LocaLisa system (Medtronic) was used as an additional tool to fluoroscopy for catheter position control during energy delivery.
Study end points
The end points of the study are: SR maintenance during the first 2 months after PVI, a proarrhythmic event during this period, and SR maintenance during at least 2 years of follow-up.
Statistical analysis
Continuous data were presented as mean values with standard deviation or as mean values with media. Differences among continuous data were evaluated by Student's t-test. Categorical data were presented as numbers and percentages, and compared with Pearson's c 2 test. The relationship among continuous data was tested with the Spearman rank correlation coefficient. Differences among the three groups were tested with one-way ANOVA. Multivariate analysis was performed with the linear regression method. The statistical significance level was p < 0.05. Data were analyzed with the STATISTICA (Statsoft Poland) software. Table 1 shows the clinical and demographic data of the patients. The study population consisted of 180 patients (mean age of 50.2 ± 11.2 years, 123 males). In 36 patients, a persistent form of AF was recognized.
Results

Two months after ablation
A total number of 180 patients were randomized into one of the following three groups: -Group 1 (G1): without antiarrhythmic agent (60 patients); -Group 2 (G2): with amiodarone (30 patients) or sotalol (32 patients); -Group 3 (G3): with last ineffective antiarrhythmic agent (58 patients). Two patients randomized to G3 received sotalol before PVI; therefore, they were moved to G2. Reliable data after 2 months were available in 171 patients (G1: 57 patients; G2: 59 patients; G3: 55 patients). Table 2 presents the groups' characteristics.
Occurrence of end points
Early period after PVI. During first 2 months after PVI, 84 (49.1%) patients were free of any AF recurrence, 35 (20.4%) experienced a single episode of AF, 39 (23%) showed an insignificant reduction in AF burden, and 13 (7.5%) presented no change in clinical status. Table 3 presents the frequency of particular end points. In Group 2, there was a higher number of persistent AF patients than in the other groups (G1 vs. G2 vs. G3: 14% vs. 28.8% vs. 16.3%; p = 0.08).
In G1, 31 (54.3%) patients maintained SR, and 9 (15.7%) patients experienced a single episode of AF. In 40 (70%) patients, the PVI procedure was successful during short-term observation (summary of SR and single AF episode). In the other groups, the results presented were: G2: 28 (47.5%) patients with SR; 9 (15.2%) patients with single AF episode -summary successful PVI in 37 (62.7%) patients, G3, respectively: 25 (45.5%) patients; 17 (30.9%) patients -summary 42 (76.4%) patients, which was statistically insignificant. No independent risk factor for early recurrence of AF was found in the multivariate analysis. More than 90% of all AF recurrences occurred during the first 30 days of observation (22 ± 13.5).
To check for the impact of any antiarrhythmic treatment, the results obtained during the first 2 months after PVI were analyzed for frequency of AF recurrences in two subgroups: G1 and cumulative G2 and G3 (Table 4) .
Long-term results. During the mean 55-month observation period, reliable data were available in 137 (80.1%) patients. During this time, 47 patients maintained SR, equivalent to 34% of the study group. Patients with repetitive PVI were classified under AF recurrence, and the final PVI Table 3 . End point occurrence in the study group during 2 months of observation. P value for G1 vs. G2 vs. G3; abbreviations as in Table 2   Table 2 . Characteristics of the study group with short-term follow-up. results were not included in further analysissome of repetitive PVI were performed in different center. There were statistically significant differences among groups with SR and AF recurrence: patients with successful PVI were younger (44.8 ± 12.7 vs. 52.5 ± 9.9 years; p = 0.0001), had no hypertension (34% vs. 53.3%; OR 2.2; 95% CI 1.06-4.6; p = 0.04), and had a smaller left atrial diameter (4.05 ± 0.49 cm vs. 4.25 ± 0.55 cm; p = 0.04) ( Table 5) .
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The findings obtained from the mean 55-month observation period showed that the antiarrhythmic strategy during the first 2 months of follow-up does not impact long-term results. Among patients with SR during the first 2 months after PVI, 78.7% had no AF recurrence during long-term follow-up, compared with 35.6% in the early recurrence group (p < 0.0001; Table 6 ). In summary, the long-term success rate in patients with SR during the first 2 months after PVI was 53.6%, whereas in patients with even one single early recurrence of AF, the percentage dropped to 26.3% (Fig. 2) .
Hypertension and persistent AF were independent risk factors for AF recurrence in longterm observation: 0.618; 95% CI 0.395-0.842; p < 0.001 and 0.48; 95% CI 0.103-0.857; p = 0.014, respectively. Categorical variables presented as sums and percentages; continuous variables presented as averages and standard deviation (SD). AF duration, persistent AF and number of AF episodes/month -pre-ablation data; AF -atrial fibrillation; SR -sinus rhythm 
Discussion
This study aimed to verify the hypothesis that AAD impact the results of PVI during the early period. Long-term verification, although difficult, was also performed. Our single-center study group consisted of consecutive patients qualified for PVI, which makes the whole group more representative of the general population.
Influence of post-ablation antiarrhythmic prophylaxis on AF recurrence frequency
This study found no association between antiarrhythmic strategy and PVI results during the early period after radiofrequency ablation, which is opposite to previously published data [11] . In the 5A study Antiarrhythmics After Ablation of Atrial Fibrillation, Roux at al. [11] assessed antiarrhythmic prophylaxis during the first 6 months after PVI. A total number of 110 patients were randomized into two groups: those using AAD and those without any prophylaxis. The clinical characteristics of the patients presented in this study were similar to those in the 5A study population; however, persistent AF patients were excluded in the latter. In the 5A study, AAD resulted in a significant reduction in number of AF recurrences, hospital admissions, cardioversions, and drug change due to symptomatic atrial arrhythmias: 19% in the AAD group vs. 42% in those without AAD (p = 0.005). Why do these two similar studies show opposite results? The answer may lie in the study methodology and the assessment criteria for the end result. First of all, the study population was different: in our study, both paroxysmal and persistent patients were included, but prior PVI was a criterion for exclusion. Persistent AF patients were distributed among three groups evenly. Thus, the reason may be the difference in the definition of AF recurrence. In both studies, every atrial tachyarrhythmia was treated as AF recurrence, but in the 5A study, the time criterion was different from that recommended in the guidelines. That is, the 5A study specified that arrhythmia should last at least 24 h or that the symptoms should lead to earlier cardioversion; according to the guidelines, this time criterion should be 30 s. The definition of recurrence in the 5A study may lead to underestimation of the real number of arrhythmia episodes in a study group. Such a definition seems controversial, especially in the continuation of the 5A study where, during 6 months of observation, AF recurrence was defined as lasting 60 s or more [12] . In our study, the AAD group was divided to check the hypothesis that AAD that is ineffective before ablation may be successful in AF prevention after PVI. The results presented in this study showed that this hypothesis is false. To compare the results of both studies, a separate analysis was made on patients without AAD vs. those receiving any AAD. There were no significant differences in recurrence rate in both groups.
AF recurrence risk factors during the early period after PVI
This study found no risk factor for early AF recurrence (EAFR) after PVI. Other studies obtained similar results, even with the definition of early period extended to 3 months and ECG registration with loop recorders [13] .
More than 90% of all EAFR occurred within the first 30 days after PVI (mean of 22 days). These data are also consistent with those previously published: 54% EAFR during the first 2 weeks after PVI, 38% occurring during the next 2 weeks, and at least one clinically significant AF episode in 65% of patients [13] . In case of any symptoms suggesting arrhythmia recurrence, a standard ECG was performed. Hindricks et al. [14] screened patients before and after PVI. They reported that before PVI, only symptomatic AF episodes occurred in 38% of patients, both symptomatic and asymptomatic ones in 57%, and only asymptomatic arrhythmia in 5%. During 6 months of observation after PVI, only asymptomatic AF was registered in 37% of patients. Asymptomatic AF recurrences are not only a matter of success assessment. In case of highly symptomatic AF before PVI, patients with asymptomatic arrhythmia after ablation consider 
